Delving into the Latest Updates on Targeted Neoantigen Haploidentical T Cell Injection(BGI Genomics) with Synapse

Overview

Basic Info

Drug Type

T-lymphocyte cell therapy

Synonyms

hNeo-T

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases

Active Indication

T-Cell Lymphoma

Inactive Indication-

Originator Organization

BGI Genomics Co., Ltd.

Active Organization

BGI Genomics Co., Ltd.

Inactive Organization-

Drug Highest PhaseEarly Phase 1

First Approval Date-

Regulation-

Login to view timeline

Objective: To evaluate the safety and tolerability of hNeo-T injection in patients with relapsed or refractory EBV-positive T-cell lymphoma.
Secondary objective: To evaluate the effectiveness of hNeo-T injection, and to evaluate the objective response rate (ORR) and disease control rate (DCR) by Lugano2014 criteria; Progression-free survival (PFS), duration of response (DOR), and overall survival (OS ) followed.
Objective of the exploratory study: To investigate the in vivo process of hNeo-T injection and describe the activity and related biological functions of hNeo-T cells in vivo, including but not limited to.

Start Date01 Dec 2023

Sponsor / Collaborator

BGI Genomics Co., Ltd.

[+1]

100 Clinical Results associated with Targeted Neoantigen Haploidentical T Cell Injection(BGI Genomics)

Login to view more data

100 Translational Medicine associated with Targeted Neoantigen Haploidentical T Cell Injection(BGI Genomics)

Login to view more data

100 Patents (Medical) associated with Targeted Neoantigen Haploidentical T Cell Injection(BGI Genomics)

Login to view more data

100 Deals associated with Targeted Neoantigen Haploidentical T Cell Injection(BGI Genomics)

Login to view more data